Bone disorders affect millions of people worldwide and current treatments have a limited efficacy often accompanied by side effects. The discovery of novel bone anabolic compounds with either pharmaceutical or nutraceutical value is thus needed. The zebrafish have emerged as a model for human bone diseases but also as a system for the screening of compounds that would treat or prevent these diseases. Beyond the technical advantages over traditional models (e.g. rodents), the high similarity of targets, physiology, drug metabolism and pharmacology in comparison to humans further highlight the potential of zebrafish as a robust model for drug screenings. The BISOKEL lab (CCMAR, University of Algarve) has developed several zebrafish assays to evaluate the osteogenic potential of natural or synthetic compounds and molecules and would like to share, within the scope of a training school (TS), both the theoretical and practical knowledge required to go through all the steps of those procedures.
Register Here: https://www.ccmar.ualg.pt/webform/zebrafishscreening
Objectives
This hands-on TS aims at providing advance training to both academia and company personnel on the use of specific zebrafish systems toward drug screening, in particular bone anabolic compounds. It will also foster knowledge exchange between attendees and contribute to the establishment of scientific collaborations on bioprospection using zebrafish. Specifically, this TS will transfer conceptual and practical known-how on the following topics:
- Basis of zebrafish biology and husbandry;
- Current knowledge on drug screenings;
- Routes of compounds exposure in zebrafish;
- Imaging of bone structures and morphometric analysis;
- Assessment of compound osteogenic and regeneration potential.
Eventos relacionados
